SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

What happens when you give Claude Code a blank webpage, and full control?

The Best Website Ever

The crypto asset BWE is trending negatively, with community sentiment focused on anticipated 'dumps' and shorting opportunities. Discussions include concerns about potential dilution, comparisons to a 'casino,' and broader anxieties related to market crashes and economic factors like tariffs and rate hikes.

SSgA Active Trust - Consumer Discretionary Select Sector SPDR

Consumer Discretionary Select Sector SPDR Fund

The Consumer Discretionary Select Sector SPDR Fund ($XLY) is trending as traders assess the strength of the consumer amid mixed signals. Recent data points, including retail sales and consumer confidence, are being weighed alongside potential impacts from tariffs and concerns about a slowing economy. Community discussion revolves around key support and resistance levels, as well as potential sector rotation and signals from related stocks like $TSLA and $AMZN.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as the community discusses its potential for a breakout, pointing to its historical significance as "silver to Bitcoin's gold." Conversations also revolve around the implementation of MWEB for enhanced privacy and scalability, with some anticipating a significant price surge. Despite some skepticism, many community members express optimism for Litecoin's future, citing its established utility and upcoming developments.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is trending as the community discusses recent price action and its potential for an upcoming bull run, with some speculating about its quantum-resistant properties and the potential impact of new partnerships. The Folks Finance airdrop is also generating buzz, as users share their experiences with claiming tokens and discuss the DeFi landscape. Some traders believe a breakout is coming, while others remain skeptical about ALGO's long-term prospects.

Freeport-McMoRan, Inc. engages in the mining of copper, gold, and molybdenum. It operates through the following segments: North America Copper Mines, South America Operations, Indonesia Operations, Molybdenum Mines, Rod and Refining, Atlantic Copper Smelting and Refining, and Corporate and Other. The North America Copper Mines segment operates open-pit copper mines in Morenci, Bagdad, Safford, Sierrita, Miami in Arizona and Chino, and Tyrone in New Mexico. The South America Operations segment includes Cerro Verde in Peru and El Abra in Chile. The Indonesia Operations segment handles the operations of the Grasberg minerals district that produce copper concentrate containing significant quantities of gold and silver. The Molybdenum Mines segment includes the Henderson underground mine and Climax open pit mine, both in Colorado. The Rod and Refining segment consists of copper conversion facilities located in North America and includes a refinery and rod mills. The Atlantic Copper Smelting and Refining segment smelts and refines copper concentrate and markets refined copper and precious metals in slimes. The Corporate and Other segment offers other mining and eliminations, oil and gas operations, and other corporate and elimination items. The company was founded by James R. Moffett on November 10, 1987, and is headquartered in Phoenix, AZ.

Freeport-McMoRan Inc

FCX is trending as investors digest recent news, including revisions to Freeport's production outlook and analysts weighing in. Community discussions revolve around the impact of these factors on FCX's valuation and future prospects amid fluctuating copper prices and demand, while institutions increased their stakes.

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Cel-Sci Corp.

CVM is trending due to speculation surrounding the impending decision from the Saudi Food and Drug Authority regarding its application for Breakthrough Medicine Designation for Multikine, with the 60-day review period nearing its end. Community members are actively discussing the potential impact of a positive or negative outcome, including its effects on partnerships, revenue, and future trials. Disagreements and heated discussions among investors regarding the company's prospects and management add to the volatility.

Kusama is a public blockchain network that is running the exact same codebase as Polkadot. It is aimed to be a canary build for the Polkadot network which is an experimental and development environment for new features that will eventually be deployed to Polkadot. Because of the experimental nature of Kusama, the developmental speed is much faster and it has seen significant traction since launched in 2019.  Kusama is an early, highly experimental version of Polkadot presenting real economic conditions. The community will own the network – there will be no central kill switch. Kusama will exist as long as its community maintains it and we envision it will cater to new, early functionality and projects preparing to develop and deploy on Polkadot.

Kusama 

Kusama is trending as traders discuss its potential for significant gains, drawing comparisons to Zcash's performance and past highs. The community is actively watching for a breakout above a key price level, anticipating a rapid surge. Discussions also mention the upcoming Polkadot and Kusama Network Migration.

BlackRock Institutional Trust Company N.A. - iShares U.S. Real Estate ETF

iShares US Real Estate ETF

The iShares US Real Estate ETF ($IYR) is trending as investors weigh the impact of rising rates and potential rate cuts on the real estate sector. Community discussions include concerns about commercial real estate weakness and potential breakdowns, while some traders point to insider buying and breakouts in specific real estate tech stocks. Divergence between gold and death cross indicators, along with comparisons to past housing market collapses, adds to the uncertain outlook.

TON (The Open Network) is a general-purpose blockchain that allows developers to build decentralized apps and tokens.

Toncoin

Toncoin is trending amid discussions around its integration with Telegram and potential for increased adoption. Community members are weighing in on its market performance, tokenomics, and recent news, including exchange listings and treasury management strategies. Some investors are also closely monitoring the relationship between TON and TONX, a related stock, for arbitrage opportunities.

eCash (XEC) is a Layer-1 digital cash network, developed by Bitcoin ABC. It was created on Nov 15th, 2020, and has since distinguished itself from its predecessors and other Bitcoin clients by integrating the breakthrough Avalanche consensus with its core proof-of-work (PoW) layer, extending its security and fundamental capabilities.  This hybrid consensus integration gives it unique properties for a Bitcoin-like chain, such as interoperability, staking rewards, real-time processing, and an improved overall extensibility, which is hard to achieve in a completely trustless manner using only Nakamoto consensus.  The development roadmap is set with three main goals: Scaling transaction throughput from ~100 tps to more than 5.000.000 tps Improving the payment experience with a less than 3 second transaction finality time Extending the protocol and establishing fork-free upgrade routines, allowing for more rapid, iterative development

eCash

eCash ($XEC) is trending due to anticipation surrounding its upcoming network upgrade on November 15, which includes Avalanche Pre-Consensus. The community is excited about the promise of instant finality and faster transaction processing that the upgrade is expected to bring to the peer-to-peer digital cash system. Several exchanges have also announced support for the upgrade.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FibroGen, Inc. (FGEN) on Monday said that a Chinese regulator has approved the sale of its unit FibroGen International (Hong Kong) to AstraZeneca (AZN).FibroGen had announced the sale of its China unit to AstraZeneca for about $160 million in February. The closing of the transaction is now expected in the third quarter of 2025, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-approval-sale-fibrogen-china-astrazeneca">said</a>. &nbsp;The closing of the transaction remains subject to other contractual closing conditions and deliverables, the biopharmaceutical company added. The firm had previously expected the transaction to close by mid-2025. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/FGEN">FGEN</a> trended in the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.The company said earlier this year that it would repay its term loan facility to investment funds managed by Morgan Stanley Tactical Value following the closing of its transaction in a bid to simplify its capital structure. The transaction is further expected to extend the company’s cash runway into 2027, it added.Upon closing, AstraZeneca will obtain all rights to Roxadustat in China. Roxadustat is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients, irrespective of whether they are on dialysis.The company is currently considering a development plan for Roxadustat in anemia associated with lower-risk myelodysplastic syndrome in the U.S. Myelodysplastic syndromes (MDS) are a group of cancers where bone marrow doesn't produce enough healthy blood cells.FGEN stock is down by 28% this year but up by about 1% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-slips-under-116000-while-cardano-solana-lead-altcoin-selloff/chsO7iYRdQw">Bitcoin Slips Under $116,000 While Cardano, Solana Lead Altcoin Selloff</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mission Bay headquarters and sign for FibroGen, a biotechnology company producing recombinant gelatins for medical devices and pharmaceuticals, San Francisco, California, 2016. (Photo by Smith Collection/Gado/Getty Images).

Fibrogen Gets Regulator’s Green Light To Sell China Unit To AstraZeneca

The company expects the transaction, which was announced in February, to close in the third quarter of 2025.

Equity

The company expects the transaction, which was announced in February, to close in the third quarter of 2025.


FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of -50.22% and -53.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates

FibroGen Executives Depart Amid U.S. Operations Overhaul

The latest update is out from FibroGen ( ($FGEN) ). FibroGen, Inc. is streamlining its U.S. operations with a significant cost reduction strategy...

Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments

Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments PR Newswire...

FibroGen Stock Is Surging After The Bell: What's Going On?

FibroGen shares are moving higher in Monday's after-hours session after the company announced the FDA cleared its Investigational New Drug (IND) FG-3165. The company also announced a new clinical...

Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates

Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates PR Newswire...

FibroGen Shares Climb On Strong Q1 Sales

FibroGen reported quarterly losses of 33 cents per share which missed the analyst consensus estimate of $(0.31) and represents a 59.26% increase year-over-year. Quarterly sales clocked in at $55.902...

Notable Wednesday Option Activity: FGEN, PLCE, MDB

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in FibroGen Inc (FGEN), where a total volume of 13,026 contracts has been traded...

Commit To Buy FibroGen At $1, Earn 44.2% Annualized Using Options

Investors eyeing a purchase of FibroGen Inc (FGEN) stock, but tentative about paying the going market price of 1.30/share, might benefit from considering selling puts among the alternative...

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.

FibroGen Inc

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

Current Price	$11.03
Prev Close	$11.00
Open	$11.00
Dividend Yield	0.00%
50-Day Moving Average	$11.42
Beta	1.74
Avg. Volume	24,490.09
PE Ratio	-21.10

52-Week High	$21.94
52-Week Low	$4.50
Market Capitalization	$44.6M
EPS (Annual)	-$11.89
Price to Book	-0.20
Revenue Per Employee	$131,648.89
Enterprise Value/EBITDA	N/A

FGEN
FibroGen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FGEN News

FGENFibroGen Inc